While much of the clothing and footwear industry has spent this earnings season explaining away low consumer demand, Birkenstock Holding plc (NYSE:BIRK) showed an entirely different story, and investors rewarded it accordingly.
Shares of the German footwear manufacturer rose up to 20% on August 13 after the company published fiscal third-quarter earnings that exceeded expectations and prompted management to improve its full-year guidance. Revenue for the quarter came in at €720 million (about $829 million), up 13% on a reported basis and 15% in constant currency, exceeding ****** ysts expectations of around €713-715 million. Meanwhile, adjusted earnings per share of €0.74 happened to be somewhat lower than the €0.76 consensus, though this fact did little to dampen enthusiasm given the report's overall strength.
The headline change was direction. Birkenstock Holding plc (NYSE:BIRK) now targets fiscal 2026 revenue growth of 15% on a constant-currency basis, up from its previous range of 13% to 15%, putting the company at the upper end of its own previous objective rather than just reiterating it. Management also increased its adjusted EBITDA forecast to at least €710 million, up from a previous floor of €700 million, and now expects reported revenue to be at the high end of the €2.30 billion-€2.35 billion range.
According to Birkenstock Holding plc (NYSE:BIRK), the reason for some of the strength is simple: full-price demand from affluent buyers who haven't reduced their discretionary spending in the same manner that the broader consumer has. Strong pricing power and brand loyalty helped shield companies catering to wealthier customers from the broader spending pullback affecting much of the apparel and footwear sector, and Birkenstock's results reflect this across all regions it operates in, with the Americas growing 14%, EMEA 15%, and Asia-Pacific rising the fastest at 23%, all in constant currency terms.
Birkenstock Holding plc (NYSE:BIRK) has also carefully managed its balance sheet during this period of strength. On June 30, the company executed an accelerated share buyback program of €230 million, decreasing its outstanding share count by about 6 million shares. The move helped enhance per-share earnings growth, with adjusted EPS rising 19% year-over-year.

#million #birk #company

By Nupur Anand and Jonathan Stempel
NEW YORK, Sept 10 (Reuters) - As U.S. President Donald Trump pressures institutions he views as adversaries, JPMorgan Chase and Capital One are fighting back. It is a strategy that legal experts and industry sources say may carry fewer risks than giving in.
Trump and his businesses are suing the banks, alleging they closed his accounts in 2021 for political reasons. They deny ‌the claims. Capital One told a federal court in July that it closed Trump's accounts following an internal anti-money-laundering review, sparking renewed scrutiny including from a senior Democratic senator who last week pressed the bank ‌for more details.
Capital One has not accused Trump or his businesses of money-laundering. Spokespeople for both banks declined to comment. The Trump Organization last week called the anti-money-laundering review a pretext to conceal a politically motivated decision.
While several legal experts said the banks have strong defenses, fighting Trump poses risks for the banks by potentially deepening animus with the president and airing confidential internal deliberations in public.

#money #laundering #president #risks

Real Madrid's La Liga journey continues on Saturday night as they play host to Rayo Vallecano on Matchday 5 of the competition.
Coming off a win over Inter Milan at the same venue, Real Madrid have bounced back strongly from their defeat against Real Betis last weekend.
The fact of the matter, however, is that the team looked unconvincing against the Serie A champions despite winning and were lucky to be gifted both their goals on the night.
There is a lot to improve on from a Real Madrid perspective, and while it will indeed take time to adapt to a new manager's ideologies, they simply cannot afford to lose any more points.
Madrid Universal brings you three talking points ahead of Real Madrid vs Rayo Vallecano.

#coming

IDEXX Laboratories, Inc. (IDXX) is a leading animal-health diagnostics and technology company best known for providing veterinarians with diagnostic testing, laboratory services, software, and imaging solutions. Valued at a market cap of $45.7 billion, the company develops and supplies diagnostic instruments, test kits, software, and laboratory services that help veterinarians, farmers, and laboratories detect diseases and monitor animal health.
Companies worth between $10 billion and $200 billion are typically classified as "large-cap stocks," and IDXX fits the label perfectly. The company is widely recognized as a market leader in veterinary diagnostics, supported by strong brand recognition, a large installed base of diagnostic instruments across veterinary practices, and a recurring revenue model fueled by consumables and testing services. With its solutions used by veterinary practices in more than 175 countries, the company has built a strong global presence and a broad, highly recurring customer base.
'Not Tens Of Billions, But Tens Of Trillions': Nvidia CEO Jensen Huang Says AI Is Like the New Electricity and the Scale Is Unlike Any Tech in History
What It Means for MSFT Stock Investors as Microsoft Switches to 2 Business Segments
RKLB Stock Jumps as Rocket Lab Debuts New Solar Cell for ******* e

#Services #Stock #laboratories

The U.S. dollar remains flat amid higher treasury yields driven by soaring energy costs. With Brent crude topping $100, worries of inflation across the globe are coming back, with the U.S. 10-year yield climbing to a 2023 high. That said, the dollar has remained unchanged, demonstrating lack of interest from investors to add long positions before the release of the upcoming US inflation data and next week's FOMC meeting.
The U.S. data on tap to influence markets is the Producer Price Index (PPI) today and Consumer Price Index (CPI) on Friday. The market currently puts odds at around 60% that the Fed may hike at its next meeting on Wednesday, following strong labor market data and increased energy shock. The energy crisis may also bring inflation concerns to investors, while the data may be weaker and may even lead market ****** ysts to turn less hawkish.
The euro zone also remains front and center. The ECB is going to hike rates by 25 bps today and mail the deposit rate at 2.50%. The consensus in the market is that the ECB will not hike again this year. Euro zone inflation was at 3.3% in August, and pressure on energy prices is building, with Deutsche Bank calling for a December rate hike.
Sterling remains subdued. The Bank of England is more cautious than its peers. There is a high consensus in the market that the BoE will hold rates on September 17. 57 of the economists polled in the REUTERS survey expect the BoE to hold for the remainder of the year. Energy concerns are high, and wage and price inflation are still muted.
As indicated in the chart, tightening by the ECB contrasts with the Fed's data dependency and the BoE's wait-and-see approach.

#energy #inflation #hike #remains

The chances of Cardinals running back Jeremiyah Love making his NFL debut against the Chargers on Sunday are looking pretty strong.
Head coach Mike LaFleur said at a press conference that Love is "trending well" ahead of the team's final practice of the week. Love injured his ankle in the team's first preseason game and has been a limited participant in practice this week. The Cardinals will issue their last injury report after Friday's practice.
Love said on Thursday that he will "fight my hardest to be out there every game this season," but said he did not know where that would happen this weekend.
The Cardinals made Love the third overall pick in this year's draft. He'll share running back duties with Tyler Allgeier to kick off his time in the league.

#game #chargers

Anne Hathaway brought fisherman sandals into the summer-to-fall stretch at New York Fashion Week on Thursday. The actress attended the Moncler Fifth Avenue flagship opening in New York City with her husband, Adam Shulman, wearing The Row's black leather Capri Knotted Slides with a relaxed double denim ensemble. Anne Hathaway and Adam Shulman attend Moncler Fifth Avenue flagship opening at 767 Fifth Avenue on Thursday in New York City. GC Images Made from pebble-grained leather, the backless flats feature knotted straps, cutouts along the sides and toe and a flat round heel. The shoes may have been the most understated part of the Erin Walsh-styled outfit, but they made a strong case for one of fashion's most useful transitional styles. With the seasons beginning to shift, Hathaway delivered an easy styling lesson for when the weather is unpredictable: wear a shoe that can do both. Anne Hathaway at the Moncler Fifth Avenue opening **** tail party and dinner held at the Moncler Fifth Avenue flagship on Sept. 10 in New York. Gilbert Flores Fisherman sandals sit somewhere between a classic sandal and a closed-toe shoe, making them particularly appealing for those in-between days when summer sandals feel too bare but a full shoe feels too heavy
Follow Footwear News on Twitter or become a fan on Facebook.

#avenue

Tucker Kraft remains one of the Green Bay Packers' biggest unresolved situations heading into Week 1. Green Bay has yet to reach an agreement on a contract extension with the young tight end, while the team also awaits a timetable for Josh Jacobs' potential NFL discipline amid his legal issues.
Adam Schefter weighed in on Kraft's contract talks with Green Bay, urging the tight end to think twice before walking away from guaranteed money that could be available to him.
"He's coming off a torn ACL and the Packers have a relatively strong offer out there. I think it's hard coming off an ACL to turn down real money," the NFL ****** yst commented during his appearance on The Pat McAfee show.
Jan 12, 2025; Philadelphia, Pennsylvania, USA; Green Bay Packers tight end Tucker Kraft (85) reacts after the game against the Philadelphia Eagles in an NFC wild card game at Lincoln Financial Field. Mandatory Credit: Bill Streicher-Imagn Images
Christian Gonzalez and Baker Mayfield showed that players can hold their ground during contract talks without letting negotiations drag into the regular season. Schefter cited both cases as examples for Kraft, who is still trying to secure his next deal with Green Bay.

#philadelphia

The New York Giants and Dallas Cowboys are set to kick off the 2026 regular season, which means fantasy football is in full swing.
With drafts already taken place, the majority of lineups are going to reflect the order in which managers drafted. Even so, there are still a handful of players who may be on the fringe in terms of their fantasy viability in Week 1.
We're not counting the likes of CeeDee Lamb, George Pickens, Malik Nabers and Javonte Williams — all of whom should be started without thought.
Meanwhile, here's a look at five players from this matchup to start or sit in Week 1:
Both quarterbacks should be in fantasy lineups this week to open the season, but we're going to focus a bit more on Dart here. Though the second-year quarterback was going relatively late in drafts, he's in a fantastic spot this week. The Cowboys defense has gotten better, but they still allowed the most fantasy points per game (23.4) to the quarterback position last season. Given that and his rushing upside, Dart is a strong option at quarterback.

#week #going

The FSU baseball program has landed its fourth player in the 2028 recruiting class, and it is yet another in-state prospect, with two-way player Garrett Harper committing on Thursday.
"Officially committed to Florida State University! 🍢 Thank you to my parents, family, friends, coaches, teammates, and Brad for believing in me and helping me get here." he wrote on social media. "Thank you to FSU for the opportunity to continue my academic & baseball journey. Time to work!"
Harper is a left-handed pitcher and outfielder from Cocoa Beach, Florida. He was originally a member of the 2029 recruiting class, but reclassified to join the 2028 class in April. He has a great frame at 6-foot-4 and 205 pounds.
He had a strong freshman season at Cocoa Beach High School and is looking to take another step as a junior after skipping his sophomore season. He finished the season hitting .442 with nine doubles, one home run, 19 RBI, and 27 runs in 29 games. He recorded a .509 on-base percentage, walking 11 times and striking out twice.
He made 12 appearances on the mound, going 3-0 with a 2.07 ERA in 44 innings. He held opponents to a .179 batting average, allowing 26 runs (13 earned) on 28 hits and 30 walks, striking out 69 batters. He faced 190 batters and did not allow an extra-base hit.

#class #harper #thank #cocoa

The Jacksonville Jaguars are facing the Cleveland Browns in Week 1 of the 2026 NFL season, and while experts are widely expecting the Jaguars to walk away with an easy win, that doesn't mean Jacksonville shouldn't take this game seriously.
The Jaguars have been extremely underrated this offseason, despite their success last year, and ***** ysts had already all but decided Jacksonville will not only not win the AFC South again, but will miss the playoffs altogether.
While the Browns may not pose much of a challenge in Week 1, the stretch of games following it are much tougher, which makes it all the more important for the Jaguars to send a strong statement to open the season. Here are five keys to a Jacksonville victory in the game.
The Jaguars' run game is one of the biggest question marks going into 2026, but pushing the run game will be more important than just proving Jacksonville still has a good running back room without Travis Etienne. Cleveland's defense was better against the pass than the run, so the Jacksonville offense should avoid playing into the Browns' strength. Jared Verse is an elite pass rusher, and he and the secondary will almost certainly be gunning for Trevor Lawrence.
Establishing the new look backfield will keep the offense out of obvious passing situations, and prevent Cleveland's pass rush and secondary from dictating the game.

#Browns #season #important

George Pickens was the biggest story the Cowboys had going through the early part of the offseason as his contract situation worked its way to an eventual franchise tag, but then the first mandatory workouts arrived, and Pickens showed up with a smile on his face and proceeded to have a strong August camp.
If that has Cowboys fans excited, so should Pickens' thoughts on where he and CeeDee Lamb rank among the league's receiving duos. Hint: He thinks they rank highly.
More: After Oklahoma rout, UTEP football team faces different kind of pressure
The Dallas Cowboys' injury report is pretty bare, which is good for an opener, while Quinnen Williams is growing into wearing the captain's patch. Here is Dallas' day.
More: Dallas Cowboys schedule 2026: Teams, time, how to watch 2026 NFL games

#ceedee

During the first 30 years of the Baltimore Ravens' story, they and the Indianapolis Colts have met 18 times. That includes three postseason matchups, but Sunday's opener carries a different feel. The Ravens are entering a new era under head coach Jesse Minter, while the Colts hope to prove they can contend in the AFC after last season's disappointing finish.
Most of the attention this week has focused on Lamar Jackson, Derrick Henry, Jonathan Taylor, Baltimore's revamped coaching staff, and what to expect on offense and defense. All of that will certainly influence the outcome, but several less-discussed storylines could play an equally important role. Here are five worth monitoring in Week 1.
Fair or unfair, Rashod Bateman enters the season under a microscope. The veteran receiver is attempting to move forward after a difficult 2025 campaign and an offseason that generated headlines for reasons unrelated to football.
A strong opener would immediately help shift the conversation back toward his on-field value. A quiet performance, however, could reignite many of the same questions that followed him throughout the offseason. One game should not define a season, but Week 1 often shapes perception. Bateman doesn't need a 100-yard performance to make an impact. He needs to remind everyone why the Ravens still believe in him.
Ja'Kobi Lane spent much of the summer generating excitement, while Vega Ioane appears poised to play a meaningful role immediately. They are not the only rookies worth watching. Pass rusher Zion Young could find himself in situations where a single splash play changes the trajectory of his debut.

#worth

BVB has never lost a competitive match against SC Paderborn: There have been two DFB-Pokal clashes, both of which saw the Black and Yellows advance to the next round. In the Bundesliga, Borussia has won two matches so far, with two others ending in draws. The most memorable encounter to date was the last Bundesliga match between the two sides at the end of May 2020. In that COVID-19-related match played behind closed doors in Paderborn, the Black and Yellows had a weak first half but stepped up their game after the break. All seven goals in the 6-1 victory came in the second half. Jadon Sancho (3), Thorgan Hazard, Achraf Hakimi, and Marcel Schmelzer—scoring his final professional goal—found the back of the net for BVB.
Best Start in Four Years With six points from two games, BVB has made its strongest start to the season in four years.
Sharp-shooting forwardSerhou Guirassy got on the scoresheet in Sinsheim with the goal that made it 1–2. The forward has been involved in three of BVB's five Bundesliga goals this season and has scored in four consecutive matches across both seasons.
Paderborn, a newly promoted team struggling to find its footing, arrives at SIGNAL IDUNA PARK with one point and still no goals scored. That said, the East Westphalians have already registered 23 shots on goal.
Milestone Within ReachBVB has achieved three wins to start the Bundesliga season only four times in its history (most recently in 2015–16). Now this milestone is once again within reach for the Black and Yellows.

#yellows #match #goals #goal

By Alexander Cornwell and Rami Amichay
TEL AVIV/PSAGOT, West Bank, Sept 9 (Reuters) - Israel has given Britain 30 days to close its East Jerusalem consulate in response to sanctions on goods from settlements, a measure Britain's leader said on Wednesday was needed to "stand against injustice" in the occupied West Bank.
In the West ‌Bank, where Israeli settlements have eaten into territory Palestinians seek for a state, settler business owners said the sanctions — announced on Tuesday by Britain, France and Canada — ‌would dent their revenues and at least one said they could force him to close his date farm.
The sanctions are among the strongest collective actions taken by Western countries that Israel once counted as close allies, highlighting its growing isolation over the war in Gaza and expansion of settlements in occupied territory.
ISRAEL SETS DEADLINE FOR BRITAIN TO CLOSE CONSULATE

#britain #sanctions #settlements

For its Q3 FY26, ABM Industries Inc. (NYSE:ABM) posted a record topline figure of $2.3 billion. With year-over-year acquisitive growth and organic expansion of 2.1% each, the total jump in sales was 4.2%. The company's adjusted EBITDA for the quarter climbed 11% to $139.6 million, compared to Q3 FY25. Adjusted net income stood at $61.5 million, exhibiting a 19% growth and translating into an adjusted diluted EPS of $1.04. ABM generated operating cash flows for the third quarter totaling $146.8 million, while free cash flow stood at $128.4 million.
Dmitry Kalinovsky/Shutterstock.com
Third quarter print revealed that majority of the topline growth was concentrated across the company's Aviation, and Manufacturing & Distribution (M&D) segments, which expanded 12.5% and 17.6% respectively. Performance within the M&D segment was driven by strong technology market trends, with further support coming from ABM's acquisition of WGNstar. Aviation segment got a boost from robust demand for air travel and healthy progress around the company's newly secured London Heathrow contract.
Prudent cost management resulted in around $3 million reduction in ongoing corporate costs compared to the previous year. Overall growth in bottom line can be attributed to higher operating profits across most segments, a lower tax bill, and cut down in corporate overhead. Some of these were offset by rising interest burden due to the financing of the WGNstar transaction. The company's share buyback initiative was another factor that led to a 25% rise in diluted EPS for the quarter.
The Education segment's revenue held steady. Business & Industry (B&I) slipped 2.6%, largely in line with expectations, due to the previously disclosed loss of a major UK client and ongoing weakness along the US west coast. Technical Solutions (ATS) growth was hampered by certain deferred projects.

#Growth #adjusted #topline

On September 8, ServiceTitan, Inc. (NASDAQ:TTAN) reported its fiscal second-quarter financial results, which showed impressive growth. The company's revenue increased 21% year-over-year to $292.8 million and non-GAAP free cash flow reached a record $50.5 million. The company's non-GAAP operating margin also improved to 15.2%.
A key highlight of the quarter was the growing adoption of ServiceTitan, Inc.'s (NASDAQ:TTAN) AI-powered Max package. The company exceeded its target as the number of Max locations more than doubled during the quarter. It now expects to reach more than 700 Max locations by the end of the fiscal year.
The company also said that it is currently focusing on Max and AI, as these represent the highest return on investment. However, this also means that the company is deferring expansion into new commercial trades.
GTV Growth Slows Despite Strong Results
While overall results were solid, ServiceTitan, Inc. (NASDAQ:TTAN) saw some moderation in gross transaction volume (GTV) growth. GTV increased 17% year-over-year in the fiscal second quarter, down from the 23% growth seen in the first quarter. The company attributed the slower growth mainly to lower lead volumes among customers, particularly in the HVAC market.

#NASDAQ

Two cybersecurity heavyweights, Rubrik, Inc. (NYSE:RBRK) and CrowdStrike Holdings, Inc. (NASDAQ:CRWD), both released Q2 FY2027 earnings in late August/early September while deepening their strategic alliance. On September 1, the companies announced a joint agentic identity resilience workflow orchestrated by CrowdStrike's Charlotte Agentic SOAR. By uniting CrowdStrike's Falcon Next-Gen Identity Security with Rubrik's Identity Resilience, joint customers can now detect, investigate, and recover from compromised identity environments in hours instead of days.
Den Rise/Shutterstock.com
CrowdStrike continues to operate at a massive scale with strong cash generation and expanding margins. For Q2 FY2027, CrowdStrike reported total revenue of $1.47 billion, up 26% year-over-year, with annual recurring revenue (ARR) reaching $5.84 billion (up 25%) after adding a record $333 million in net new ARR. GAAP net income turned positive at $5.3 million ($0.01 per diluted share), while non-GAAP net income reached $322.9 million ($0.31 per diluted share). Operating cash flow hit a Q2 record of $530.3 million, with free cash flow reaching $377.4 million. Expanding its momentum, CrowdStrike announced a partnership with OpenAI on September 2 to secure Codex agents and integrate GPT-5.6 Cyber into Falcon, prompting Raymond James to raise its price target to $250 from $240 on September 3, citing an "AI double whammy."
Rubrik, meanwhile, represents the hyper-growth challenger outperforming Wall Street's top-line expectations. For Q2 FY2027, Rubrik's total revenue surged 38% year-over-year to $427.3 million (up 43% when normalized for material rights), while Subscription ARR grew 33% to $1.66 billion. While GAAP net loss per share narrowed to $(0.30), Rubrik achieved non-GAAP net income per share of $0.20 ($0.47–$0.53 guidance for full FY27). Operating cash flow reached $76.8 million, generating $65.7 million in free cash flow. While CrowdStrike holds the stronger overall financial profile given its $5.84 billion ARR scale and $377.4 million free cash flow generation, Rubrik leads in top-line growth velocity.
CrowdStrike's bull case rests on its leadership in endpoint and identity security, proven GAAP and non-GAAP profitability, and deep AI integrations with platforms such as OpenAI and Charlotte AI, which could drive further platform consolidation and high-margin ARR growth. However, slower percentage growth compared with younger peers, elevated valuation multiples, and lingering customer scrutiny following past software update disruptions remain key risks.

#flow

Braze Inc. (NASDAQ:BRZE) turned in a strong second quarter. The reputed customer engagement platform showcased continued momentum across both its product strategy and financial performance. The company generated topline figure of $227.2 million, an impressive 26.2% increase compared to the same period last year. This revenue growth was fueled by upselling gains, customer additions and renewals. The company posted $24.2 million in cash flow from operating activities, a monumental growth relative to $7 million in the same period a year ago. This was paired with $21.7 million in free cash flow, against $3.5 million during Q2 FY26.
Jirsak/Shutterstock.com
The quarter brought several meaningful strategic moves. Braze broadened its BrazeAI Operator tool, which allows users to build new Canvas steps straight from conversational prompts. The company also signed a three-year Strategic Collaboration Agreement with AWS to support collaborative co-selling and go-to-market initiatives. The arrangement will incentivize AWS sellers for integrating Braze within their accounts.
For the latest quarter, subscription revenue jumped to $207.7 million from $171.8 million a year prior, while professional services and other revenue more than doubled, reaching $19.6 million. Dollar-based net retention among larger accounts, defined as those with annual recurring revenue of $500,000 or more, edged up to 112% in comparison to 111% a year earlier. Profitability metrics improved considerably as well, with adjusted operating income jumping to $22 million from $6 million, and adjusted diluted EPS increasing from $0.15 to $0.19.
Management cited growing demand for measurable return on investment as the primary force behind faster uptake of Braze's AI product lineup, which includes BrazeAI Operator, BrazeAI Agent Console, and BrazeAI Decisioning Studio.

#revenue

On September 2, F5, Inc. (NASDAQ:FFIV) announced a key integration with MuleSoft, a Salesforce, Inc. (NYSE:CRM) company, federating F5 AI Guardrails directly into MuleSoft's Agent Fabric Omni Gateway. As enterprises rapidly scale agentic AI capabilities, security teams face growing governance gaps and risks from prompt injection, data leakage, and toxic outputs. This native integration gives security and platform engineering teams centralized policy enforcement, proactive threat mitigation, and low-touch policy tuning without forcing organizations to re-architect existing infrastructure.
While the partnership strengthens both ecosystems, examining their latest financials reveals two enterprise software giants moving at distinctly different scales and growth trajectories.
F5, Inc. (NASDAQ:FFIV) reported strong Q3 FY26 results, generating $865 million in revenue (up 11% year-over-year). Revenue growth was anchored by a 19% jump in product revenue, led by a 32% surge in systems revenue ($240 million). F5's bottom line remained exceptionally robust, expanding non-GAAP operating margin to 35.0% and delivering non-GAAP net income of $272 million ($4.73 per diluted share, up from $4.16).
Salesforce operated at a much larger scale in its record Q2 FY27, generating $11.3 billion in quarterly revenue (up 11% year-over-year). Growth was fueled by subscription and support revenue of $10.8 billion and expanding adoption of its Agentforce platform, whose annual recurring revenue (ARR) neared $3.9 billion. Salesforce posted a non-GAAP operating margin of 34.1%, and non-GAAP diluted EPS of $5.90, while raising its full-year FY27 revenue guidance to $46.1B–$46.4B.
While both companies run near-identical, highly profitable non-GAAP operating margins (~34%–35%), Salesforce leads overall financial health due to its massive free cash flow generation, cRPO backlog of $33.5 billion, and broader ecosystem dominance.

#Growth

On August 27, AstraZeneca PLC (NYSE:AZN) and Amgen Inc. (NASDAQ:AMGN) scored a shared clinical victory. Positive high-level results from the Phase III CROSSING trial showed that their co-developed severe asthma drug, TEZSPIRE, achieved statistically significant and clinically meaningful improvements across both co-primary endpoints, histologic remission and the frequency/severity of dysphagia, and all key secondary endpoints at week 24 in patients with eosinophilic esophagitis. These benefits were sustained through week 52 across both tested doses, accompanied by a safety profile consistent with its approved indications. While CROSSING highlights their joint R&D success, a closer look at their standalone financial performance reveals distinct growth trajectories.
Both pharmaceutical giants delivered solid Q2 2026 results, but AstraZeneca is showing stronger overall financial momentum. AstraZeneca PLC (NYSE:AZN)'s Q2 revenue increased 6% year over year to $15.38 billion, supported by its Oncology franchise, which grew 18% in H1 to $14.12 billion, and its Rare Disease portfolio, which increased 13%. Core EPS rose 21% to $2.63, beating expectations, while management reaffirmed its full-year 2026 outlook for mid-to-high single-digit revenue growth and low double-digit Core EPS growth.
Amgen Inc. (NASDAQ:AMGN) reported Q2 revenue of $10.1 billion, up 10% year over year, while non-GAAP EPS increased 4% to $6.29. Although its key growth products advanced 26%, mature products faced significant biosimilar pressure, with Prolia revenue declining 32% and XGEVA falling 34%. Amgen nevertheless raised its 2026 revenue guidance midpoint to $39.4 billion.
Overall, AZN holds the financial edge due to stronger EPS growth, broader portfolio momentum, and less exposure to the biosimilar erosion affecting AMGN's mature products.
Amgen's bull case is supported by robust growth in key products, which increased 26%, and $3.5 billion in Q2 free cash flow, providing substantial capital flexibility. Wells Fargo raised its Amgen price target to $435 from $400 on September 4, citing potential upside from HORIZON and pipeline ****** ets such as olpasiran. New Phase III VESALIUS-CV data also showed Repatha reduced the risk of death by 20% in high-risk adults without a prior heart attack or stroke, with heart attack risk reductions emerging as early as six months. However, accelerating biosimilar competition affecting legacy franchises such as Prolia and XGEVA remains a key risk to sustained margin expansion.

#revenue #astrazeneca #increased #products

The pharmaceutical sector was hit with major pipeline news on September 1 when Novartis AG (NYSE:NVS) paused eight clinical trials of rap-cel, its experimental CAR-T cell therapy targeting autoimmune and neurological disorders. The suspension, effective August 24, followed three patient deaths caused by severe, life-threatening immune reactions (immune effector cell-associated hemophagocytic syndrome). Novartis is currently conducting a safety review alongside independent monitoring boards. Following the news, Bristol-Myers Squibb Company (NYSE:BMY) voluntarily paused trials for its competing CAR-T treatment, zola-cel, as a precautionary measure after detecting transient inflammatory side effects.
Looking at Q2 2026 earnings, Bristol Myers Squibb is currently demonstrating stronger financial momentum. Bristol-Myers Squibb Company (NYSE:BMY) reported total revenue of $13.0 billion, up 6% year over year, driven by a 15% increase in its Growth Portfolio to $7.6 billion, led by Opdivo, Qvantig, Reblozyl, and Camzyos. Non-GAAP EPS reached $2.04, while net income totaled $3.3 billion, or $4.2 billion on a non-GAAP basis. The company also raised its full-year 2026 revenue guidance from approximately $46.0–$47.5 billion to $49.0–$50.0 billion and increased its non-GAAP EPS outlook to $6.75–$7.00.
Novartis AG (NYSE:NVS), meanwhile, reported Q2 net sales of $14.4 billion, up 3% in U.S. dollars and 1% at constant currencies, supported by Kisqali and Kesimpta, which grew 43% and 32% at constant currencies, respectively. However, generic competition reduced growth by 14 percentage points, while core operating income remained flat at $5.9 billion and GAAP net income fell 19% to $3.3 billion. Novartis reaffirmed rather than raised its full-year guidance, calling for low single-digit sales growth and a low single-digit decline in core operating income.
Overall, Bristol Myers stands out as the stronger financial story this quarter, with its Growth Portfolio offsetting legacy patent-cliff pressures and supporting a guidance increase, while Novartis continues to contend with generic erosion weighing on earnings.
Novartis' bull case rests on strong double-digit growth from high-margin blockbusters such as Kisqali, Kesimpta, and Scemblix, supporting robust Q2 free cash flow of $5.6 billion. However, CAR-T safety setbacks could threaten a key pipeline platform, while intense generic competition has already reduced top-line growth by 14 percentage points.

#billion #novartis

On September 2, Shell Offshore, a subsidiary of Shell plc (NYSE:SHEL), announced the acquisition of a 30% working interest in Conifer, an exploration prospect operated by BP p.l.c. (NYSE:BP) in the U.S. Gulf of Mexico. Located offshore within Keathley Canyon near BP's Kaskida host development, Conifer represents a significant deep-water play. BP retains operatorship, with the initial exploration well expected to spud in 2027. While the deal reflects shared risk and capital efficiency in high-cost offshore basins, comparing the two giants' Q2 2026 earnings shows that Shell is currently executing from a position of superior financial strength.
Shell plc (NYSE:SHEL) delivered an exceptionally clean Q2 2026 report. Adjusted earnings reached $9.8 billion, driven by record upstream production in Brazil and record refinery utilization, which offset Middle East operational outages. Cash flow from operations (CFFO) came in at $21.4 billion, supported by higher realized prices and a $3.4 billion working capital inflow. Shell maintained strict capital discipline, reiterating its full-year capex outlook of $24 billion–$26 billion while completing $5.8 billion in structural cost reductions since 2022. Balance sheet health remains robust, with gearing at 19% and net debt at $42 billion ($12 billion excluding leases).
BP p.l.c. (NYSE:BP) also turned in a solid Q2 recovery, but its headline metrics lag behind Shell's scale. BP reported underlying replacement cost profit (its proxy for net income) of $5.7 billion, a 78% quarter-over-quarter rebound fueled by strong refining margins and oil trading. Operating cash flow reached $10.9 billion after absorbing a $1.0 billion working capital build. BP used strong cash generation to trim net debt down to $22.25 billion, while guiding full-year capex to $13.5 billion–$14.0 billion.
Although BP raised its quarterly dividend by 4% to 8.66 cents, Shell's cash engine allowed it to announce its 19th consecutive quarter of at least $3 billion in share buybacks, distributing 44% of CFFO over the trailing 12 months.
Shell's bull case centers on superior capital allocation, aggressive portfolio high-grading, including the ARC Resources acquisition targeting a 4% production CAGR through 2030, and consistent share buybacks. The bear case focuses on execution risks in integrated gas and LNG amid volatile market conditions, as well as the challenges of integrating large-scale acquisitions.

#cost

By
Listen
(1 min)
Ford Motor Chief Executive Jim Farley strongly rejected claims from Transportation Secretary Sean Duffy that the automaker was growing overly reliant on Chinese car companies, including through its business tie-ups overseas and a battery plant in Michigan.

#listen #chief

Meghan Markle and Prince Harry's UK return could have a familiar royal figure at its center. An expert claims Princess Diana's legacy may help shape their re-entry into Britain. The timing has also prompted speculation about a possible project marking the 30th anniversary of Diana's death. However, one commentator has questioned the ethics of bringing the late princess into the couple's next chapter.
According to a discussion on "The Royalist" podcast, Meghan Markle and Prince Harry could use Princess Diana's legacy to help reintroduce themselves to the British public. Host Tom Sykes was joined by Samara Gill, who discussed the timing of the couple's return and its possible connection to Diana.
Diana's 30th death anniversary is approaching in 2027. Against that backdrop, there has been speculation that the Sussexes may be working on a possible documentary focusing on the late princess. The project has also apparently been ******* ociated with Netflix. However, no documentary has been officially announced by Harry, Meghan, or the streaming platform.
For Gill, the potential project could serve a wider purpose. She claimed the couple may be looking to reconnect with the British public through Diana's enduring popularity. Gill said they could be "using Diana to relaunch" their return to the UK. She argued that the late princess remains someone "most people — the majority of the public — can get behind." By contrast, she claimed that Harry and Meghan face strong opposition from a large section of the British public.
From a public relations perspective, Gill acknowledged that the strategy could be effective. She described it as a "smart PR move." However, she also questioned the ethics of making Diana part of such a comeback. "Morally, I find it a little interesting, a little sticky and icky," Gill said. She added that the idea of using Diana in this way gave her "a bit of a sick feeling."

#princess #however #british #possible

On September 3, AbbVie Inc. (NYSE:ABBV) finalized its acquisition of clinical-stage biotech Apogee Therapeutics, Inc. (NASDAQ:APGE) for $135.11 per share in cash. The $10.9 billion buyouts immediately fold Apogee's promising inflammatory and immunology (I&I) pipeline into AbbVie's commercial engine. On the exact same day, AbbVie separately reported positive Phase 3 Cervino trial results for its bispecific T-cell engager, etentamig, in relapsed/refractory multiple myeloma. Together, the dual catalysts emphasize how mega-cap pharmaceutical giants are deploying cash flow from legacy franchises to lock in next-generation immunology and oncology ***** ets.
In Q2 2026, AbbVie Inc. (NYSE:ABBV) posted $16.99 billion in net revenue, up 10.2% year over year, while adjusted diluted EPS increased 22.9% to $3.65. Growth was driven by its immunology blockbusters, Skyrizi and Rinvoq, which generated $5.505 billion and $2.525 billion in revenue, respectively, representing growth of 24.4% and 24.5%. These gains more than offset the continued decline in Humira revenue, which fell 35.9% to $756 million amid biosimilar competition. AbbVie reiterated its full-year 2026 adjusted EPS guidance of $13.87–$14.07, including a $0.14 dilutive impact from the Apogee transaction.
As a clinical-stage biotech, Apogee Therapeutics, Inc. (NASDAQ:APGE) generated no product revenue in Q2 2026, while R&D expenses reached $67.3 million and G&A expenses totaled $24.3 million, resulting in a quarterly net loss of $85.9 million. Despite the cash burn, the company maintained a strong liquidity position, with $1.3 billion in cash and marketable securities, alongside a $1.3 billion non-dilutive credit collaboration with Blackstone Life Sciences to support Phase 3 trials of its lead ***** et, zumilokibart.
Financially, AbbVie is vastly superior in immediate cash generation and profitability, whereas Apogee represented pure clinical optionality backed by robust liquidity.
For AbbVie, acquiring Apogee's optimized antibody portfolio, including zumilokibart for atopic dermatitis, strengthens its post-Humira immunology franchise. Combined with internal R&D advances such as etentamig, which achieved statistically significant overall response rate and progression-free survival results in the Phase 3 Cervino study, along with an 87.9% 12-month overall survival rate, AbbVie demonstrates potential to sustain strong organic growth.

#phase #revenue #Growth

Hewlett Packard Enterprise Company (NYSE:HPE) announced an expanded collaboration with Oracle Corporation (NYSE:ORCL) on September 2 to scale Oracle's global AI infrastructure using HPE Juniper Networking across Oracle Cloud Infrastructure (OCI) data centers. The partnership builds on over a decade of joint engineering, leveraging HPE's routing and switching platforms to support OCI's expanding gigawatt-scale GPU superclusters. To align long-term incentives, HPE issued stock warrants to Oracle.
Following the announcement, Wall Street delivered fast price target hikes: Barclays' Tim Long raised HPE's target by $12 to $79 (Overweight), citing server upside and robust margins, while Morgan Stanley's Sanjit Singh boosted Oracle's target by $3 to $210 (Equal Weight), noting a tactically positive setup driven by GPUaaS demand.
Hewlett Packard Enterprise Company (NYSE:HPE) and Oracle both delivered strong results, although Oracle operates at a significantly larger scale. HPE reported record Q3 2026 revenue of $12.2 billion, up 34% year over year, driven by strong server demand and a 74.9% increase in Networking revenue to $2.9 billion. GAAP diluted EPS reached $1.06, while strong execution led management to raise full-year FY26 revenue growth guidance to 34%-37% and its free cash flow target to at least $3.75 billion.
Oracle Corporation (NYSE:ORCL), meanwhile, ended fiscal 2026 with record Q4 revenue of $19.2 billion, up 21% year over year, and full-year revenue of $67.4 billion, up 17%. Q4 Cloud Infrastructure (IaaS) revenue surged 93% to $5.8 billion, while full-year GAAP EPS rose 34% to $5.83 and Remaining Performance Obligations (RPO) jumped 363% to $638 billion.
Overall, ORCL leads in hyper-growth and long-term backlog, reinforcing its position as the stronger software and cloud play, while HPE is demonstrating stronger near-term hardware momentum and attractive cash flow generation for value-oriented investors.

#billion #revenue #infrastructure

Dell Technologies (DELL) shares have surged more than 316% so far in 2026, fueled by robust demand for AI infrastructure, increased enterprise investment in modernizing IT systems, and continued expansion of its customer base.
The company is also benefiting from strong demand for its AI-optimized servers, and the momentum is likely sustainable in the coming quarters. At the same time, rising AI demand is also driving demand for traditional servers and networking equipment, further strengthening Dell's long-term growth prospects.
'Not Tens Of Billions, But Tens Of Trillions': Nvidia CEO Jensen Huang Says AI Is Like the New Electricity and the Scale Is Unlike Any Tech in History
What It Means for MSFT Stock Investors as Microsoft Switches to 2 Business Segments
RKLB Stock Jumps as Rocket Lab Debuts New Solar Cell for ***** e

#tens

Apple Inc. (NASDAQ:AAPL) and Intel Corporation (NASDAQ:INTC) represent two sides of a historical silicon transition. A September 2 report from MacRumors highlighted a key milestone: Apple notified developers that universal Mac App Store apps requiring macOS 13 or later can now drop support for Intel-based Macs. Removing Intel binary slices simplifies app development and reduces download sizes. While symbolic, the move underscores Apple's completed transition to Apple Silicon and highlights Intel's diminishing footprint within Apple's high-margin ecosystem.
Financially, Apple is faring significantly better than Intel.
For Q3 2026 (ended June 27, 2026), Apple reported record quarterly revenue of $109.4 billion, up 16% year-over-year, driven by double-digit growth across iPhone, Mac, and Services. The company's gross margin reached 50.1%, supported by a 2 percentage point favorable impact from tariff refunds. Diluted earnings per share (EPS) surged 29% year-over-year to $2.02, which included a $0.11 favorable boost from tariff refunds. Operating cash flow and active installed base both set new June quarter records.
Intel's Q2 2026 financial results (ended June 27, 2026) delivered $16.1 billion in quarterly revenue, up 25% year-over-year, marking its fastest top-line growth in over 15 years. Intel reported a GAAP net loss of $11.0 billion (GAAP EPS of -$2.16), largely driven by non-cash charges and mark-to-market adjustments. However, on a non-GAAP basis, net income reached $2.2 billion ($0.42 diluted EPS), nearly doubling consensus expectations. Non-GAAP gross margin expanded to 41.8% (40.4% GAAP) on strong product mix and factory yields.
Apple's bull case centers on expanding Services margins, strong ecosystem lock-in, and the potential for Apple Intelligence to drive further demand and engagement across iOS and macOS devices, supporting high-margin growth. On the other hand, Apple faces risks from elevated valuation multiples, sluggish growth in Greater China, where Q3 revenue reached $14.7 billion, and ongoing global antitrust scrutiny over App Store fees.

#revenue

Braze, Inc. (NASDAQ:BRZE) reported strong Q2 results on September 8, but investors appeared more focused on the company's outlook. Despite the solid performance, the company's shares had fallen sharply following the earnings report, declining nearly 20% in the September 9 session.
In its second quarter of fiscal 2027, the company generated $227.2 million in revenue, up 26.2% year-over-year. Braze, Inc. (NASDAQ:BRZE) said growth was mainly driven by new customers, along with upsells and renewals from existing customers. Subscription revenue increased 21% to reach $207.7 million.
Non-GAAP net income also improved 26% to more than $21.23 million, or $0.19 per share. Revenue and adjusted earnings were ahead of Wall Street expectations. **** ysts were expecting Braze, Inc. (NASDAQ:BRZE) to report revenue of slightly more than $220 million and adjusted earnings of $0.15 per share.
The company also showed improvement in its cash generation as it reported record second-quarter cash flow from operations of $24 million and free cash flow of $22 million.
Guidance Becomes the Main Concern

#september